Blog
RSS FeedPosted by Michael Wonder on 18 Mar 2021
Investment in innovative medicines needed to safeguard Australia’s long-term prosperity
17 March 2021 - Medicines Australia has lodged its 2021-22 Pre-Budget Submission with The Treasury which outlines several recommendations to ...
Posted by Michael Wonder on 16 Mar 2021
EU regulators team up with U.S. and UK on pharmaceutical mergers
16 March 2021 - EU antitrust enforcers have teamed up with their U.S. and British counterparts to share expertise on ...
Posted by Michael Wonder on 14 Mar 2021
Pharma giants get their pennies pinched on drug pricing
12 March 2021 - The vaunted ability of pharmaceutical companies to name their own price is vanishing as middlemen increasingly call ...
Posted by Michael Wonder on 09 Feb 2021
Collaboration between the FDA and industry is essential to foster innovation in Alzheimer’s treatments
8 February 2021 - As the Food and Drug Administration moves closer to a decision about whether to approve a ...
Posted by Michael Wonder on 02 Feb 2021
If 2021 is to be the year of U.S. drug price controls, how should biopharma companies respond?
2 February 2021 - As the Biden administration assumes leadership in Washington and former President Donald Trump’s most favoured nation ...
Posted by Michael Wonder on 31 Jan 2021
Medicines Australia’s position on potential European Union restrictions and vaccines supply
30 January 2021 - Medicines Australia is concerned by the reports of proposals from Europe that could impact the global ...
Posted by Michael Wonder on 24 Jan 2021
Canada’s drug makers rattle their sabers over a government plan to control medicine spending
21 January 2021 - A majority of pharmaceutical executives in Canada say new regulations designed to cut prescription drug spending ...
Posted by Michael Wonder on 19 Jan 2021
Mark Cuban is going to help big pharma’s image
19 January 2021 - In his terrific book, The Great American Drug Deal, Peter Kolchinsky talks about one of the most ...
Posted by Michael Wonder on 12 Jan 2021
ICER identifies most significant 2019 US drug price hikes — even after rebates — that were not supported by new clinical evidence
12 January 2021 - Out of 10 identified drugs that had substantial 2019 price increases on top of already high current ...
Posted by Michael Wonder on 07 Jan 2021
Drug prices increase and biopharma bashing returns
5 January 2021 - It’s an annual ritual. In the first week of January, drug companies announce their annual price increases. ...
Posted by Michael Wonder on 15 Dec 2020
Big Pharma’s new CEOs must step up to erase inequities in drug access
16 December 2020 - I have been asked many times: Does the vision of the CEO have the power to ...
Posted by Michael Wonder on 13 Dec 2020
Reimbursement from pharmaceutical companies decreases by 288 million
11 December 2020 - The rebate from side agreements between regions and pharmaceutical companies is estimated according to the forecast ...
Posted by Michael Wonder on 13 Oct 2020
COVID-19 vaccines are chance at salvation, financial and beyond, for drug makers
13 October 2020 - Big profits beckon for pharmaceutical companies, which are already using their work on vaccines to fight efforts ...
Posted by Michael Wonder on 02 Oct 2020
Biotech industry pushes Trump Administration to release new vaccine guidelines
2 October 2020 - The BIO trade group, whose members include most of the vaccine makers, asked the health secretary to ...
Posted by Michael Wonder on 30 Sep 2020
House panel says drug makers inflated prices to boost profits and reap bonuses
30 September 2020 - The Democrat-led reports come just weeks before Election Day, and amid efforts by President Donald Trump to ...